Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 3
Submit an article Journal homepage
128
Views
55
CrossRef citations to date
0
Altmetric
Original Research

Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes

Kaspar Berneis University Hospital Zurich, Clinics for Endocrinology, Diabetes and Clinical Nutrition, Switzerland
, MD,
Manfredi Rizzo University of Palermo, Department of Clinical Medicine and Emerging Diseases, Italy
, MD,
Christoph Stettler University Hospital of Bern, Division of Endocrinology, Diabetes and Clinical Nutrition, Inselspital, 3010 Bern, Switzerland +41 31 632 40 70; +41 31 632 84 14; [email protected]
, MD,
Bernard Chappuis University Hospital of Bern, Division of Endocrinology, Diabetes and Clinical Nutrition, Inselspital, 3010 Bern, Switzerland +41 31 632 40 70; +41 31 632 84 14; [email protected]
, MD,
Monica Braun University Hospital of Bern, Division of Endocrinology, Diabetes and Clinical Nutrition, Inselspital, 3010 Bern, Switzerland +41 31 632 40 70; +41 31 632 84 14; [email protected]
, MD,
Peter Diem University Hospital of Bern, Division of Endocrinology, Diabetes and Clinical Nutrition, Inselspital, 3010 Bern, Switzerland +41 31 632 40 70; +41 31 632 84 14; [email protected]
, MD &
Emanuel R Christ University Hospital of Bern, Division of Endocrinology, Diabetes and Clinical Nutrition, Inselspital, 3010 Bern, Switzerland +41 31 632 40 70; +41 31 632 84 14; [email protected]
, MD PhD show all
Pages 343-349 | Published online: 28 Jan 2008

Bibliography

  • Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;356:2522-4
  • Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504
  • Taskinen MR. Diabetic dyslipidaemia. From basic research to clinical practice. Diabetologia 2003;46:733-49
  • Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000;23:1605-11
  • Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-34
  • Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
  • Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
  • Rizzo M, Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment. QJM 2006;99:1-14
  • Winkler K, Konrad T, Fullert S, et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 2003;26:2588-94
  • Perez A, Khan M, Johnson T, Karunaratne M. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res 2004;1:44-50
  • Parhofer KG, Otto C, Geiss HC, et al. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 – results of a pilot study. Exp Clin Endocrinol Diabetes 2005;113:49-52
  • Szapary PO, Bloedon LT, Samaha FF, et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:182-8
  • Lautamaki R, Nuutila P, Airaksinen KE, et al. The effect of PPARgamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease. Rev Diabet Stud 2006;3:31-8
  • Yu D, Murdoch SJ, Parikh SJ, et al. Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diab Vasc Dis Res 2006;3:189-96
  • Deeg MA, Buse JB, Goldberg RB, et al.; on behalf of the GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30(10):2458-64
  • Chappuis B, Braun M, Stettler C, et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007;23(5):392-9
  • Harris JA, Benedict FG. A Biometric Study of Basal Metabolism in Man. Washington DC: Carnegie Institution of Washington: Publ. No 279; 1919
  • Krauss R, Burke D. Identification of multiple subclasses of plasma low denstity lipoproteins in normal humans. J Lipid Res 1982;23:97-104
  • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death for cardiovascular causes. N Engl J Med 2007;356:2457-71
  • Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
  • Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
  • Erdmann E, Dormandy JA, Charbonnel B, et al.; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80
  • Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999;246:341-55
  • Rizzo M, Barbagallo CM, Severino M, et al. Low-density-lipoprotein peak particle size in a Mediterranean population. Eur J Clin Invest 2003;33:126-33

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.